Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Elutia Q3 2026 Results: Net Loss of $1.28M, Loss Narrows

Elutia Inc. is focusing on the development of its next-generation biologic scaffolds, NXT-41 and NXT-41x, following the divestiture of its SimpliDerm and Orthobiologics businesses. The company is managing ongoing litigation related to its FiberCel and VBM product recalls while navigating capital requirements and Nasdaq compliance.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.10.9
Gross profit0.70.5
Profit before tax-6.5-1.0
Net income-1.3-3.9
EPS (diluted, $ a share)$-0.04$-0.19

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+20.4%
Gross margin61.7%
Source

10-Q filed with the SEC, NASDAQ: ELUT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Elutia Inc.: key numbers

Share price
$0.8229Close, Nov 16
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Elutia Inc.

All →
4:06 PM ET 8-K
Financial Results

Elutia Financial Results

Elutia Inc. reported financial results for the third quarter of 2026, highlighted by 20% year-over-year revenue growth in its cardiovascular business. The company announced it is on track for a Q4 2026 FDA submission for NXT-41x, its antibacterial envelope for plastic surgery, and believes it is fully funded through 2028 commercialization after receiving $26 million in non-equity capital.

Term
Q3 2026

“We are out to solve it, and will take the next step this quarter with the NXT-41x FDA submission. After adding $26 million without an equity offering, we believe we have the technology, the team, and the capital to advance NXT-41x toward anticipated clearance in the first half of 2027 and through the first full year of commercial launch in 2028. In doing so, we will help patients thrive without compromise.”

Dr. Randy Mills, Chief Executive Officer of Elutia

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.